Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium - Based Contrast Agents

Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium - Based Contrast Agents

Friday, May 14, 2010 - Saturday, May 15, 2010

The New York Academy of Sciences

Presented By

Presented by Yale School of Medicine and the New York Academy of Sciences

 

In 1997, a new disease was recognized among patients with pre-existing renal dysfunction. Now known as Nephrogenic Systemic Fibrosis (NSF), the disorder is known to be highly associated with, and very likely triggered by, gadolinium based magnetic resonance imaging contrast agents (GBCA). As such, it is a man-made disease, very likely a hitherto uncharacterized fibrosing toxicity to heavy metal deposition in the human body. Much of what we know about NSF stems from the NSF Registry at Yale University, and, in recent years, an annual scientific meeting on NSF hosted at Yale.

The May 2010 Fourth Annual Meeting on NSF and GBCA will have several goals. As the 4th meeting represents a change in venue from New Haven, CT to New York City, a very important aspect will be introducing the disease to a new, and much larger community of practitioners and scientists, chiefly in nephrology, radiology, rheumatology, dermatology and pathology. The introductory sessions will provide the historical context of NSF—how it was discovered, the mechanics of how it is diagnosed, and the significance of gadolinium micro-detection. The core of the meeting will focus on the mechanism of fibrosis in NSF—these derived from animal and tissue culture studies. The discussion will be broadened to include known mechanisms of tissue fibrosis (systemic and organ specific) and potential targets of pharmacologic therapy. Lastly, we will examine the lessons learned from NSF: the current state of prevention, and practical strategies for using GBCA wisely in those at risk.

Overall, the breadth of discussions will extend from the cells and atoms responsible for NSF to the entire population at risk, and therapeutically and mechanistically from the scientific bench-top to the bedside. Of greater importance, perhaps, is the impact this work will have on the fundamental understanding of fibrosis in general, opening up new avenues of understanding into disease mechanisms previously thought to be unchallengeable by medicine.

For more information about this symposium, please go to the Yale CME website.

Symposium Co-Chairs

Ali K. Abu-Alfa, MD

Yale School of Medicine

Shawn Cowper, MD

Yale School of Medicine
The International Center for Nephrogenic Systemic Fibrosis Research

Scientific Program Director

Richard Bucala, MD, PhD

Yale School of Medicine

Clinical Program Director

Jeffrey Weinreb, MD

Yale School of Medicine

Consulting Faculty and Program Content Reviewer

Marcus W. Bosenberg

Yale School of Medicine

Learning Objectives

Participants who attend this conference will be able to:

  • • Receive updated information on the diagnosis and treatment of NSF.
  • • Review current understanding of the pathophysiology of NSF .
  • • Recognize important differences among the various GBCA.
  • • Discuss the impact on patient care and practice management.
  • • Discuss strategies to identify patients with kidney disease who might be at risk.


Accreditation Statement

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credit™.

Designation Statement

The Yale School of Medicine designates this educational activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

Presented by

Related Event

Inaugural Global Fibrosis Foundation Fundraising Dinner
May 14, 2010 | 8:00PM

Separate from the scientific symposium, the Global Fibrosis Foundation will hold their inaugural fundraising event. For information and to reserve tickets please visit http://www.globalfibrosis.org/funds.html or contact Carol Hribko at hribko.globalfibrosis@gmail.com.

*Image kindly donated by Shawn Cowper: Heart muscle (red) entwined in fibrous collagen (blue) from a young NSF patient (Trichrome stain)

Agenda

*Presentation times are subject to change.


Friday, May 14, 2010

12:00 PM

Registration

12:30 PM

Welcome
Ali Abu-Alfa MD, FASN, Yale School of Medicine
Shawn Cowper, MD, Yale School of Medicine, The International Center for Nephrogenic Systemic Fibrosis Research

Session I

Moderator: Henrik S. Thomsen, MD, University of Copenhagen and Copenhagen University Hospital

12:40 PM

Nephrogenic Systemic Fibrosis: Definition, Systemic Effects and Disease Course
Shawn Cowper, MD, Yale School of Medicine, The International Center for Nephrogenic Systemic Fibrosis Research

1:10 PM

Nephrogenic Systemic Fibrosis and GBCA: Radiology Revelations
Emanuel Kanal, MD, University of Pittsburgh Medical Center

1:40 PM

Update on imatinib Treatment in NSF
Jonathan Kay, MD, University of Massachusetts Medical School

2:10 PM

Refreshment Break & Poster Reviews

2:30 PM

Detection of Gadolinium in Tissues: What does it Mean, Exactly?
Whitney A. High, MD, University of Colorado, Denver

3:00 PM

NSF and GBCA: Pharmacovigilance and Regulatory Actions in the US
Ira Krefting, MD. Food and Drug Administration

3:30 PM

Q&A

4:00 PM

Platform Presentations
Moderator: Michael Girardi, MD, Yale School of Medicine

Keynote Lecture

5:00 PM

The Discovery of NSF
Philip Leboit, MD, University of California, San Francisco

5:45 PM

Reception

Saturday, May 15, 2010

7:30 AM

Registration and Continental Breakfast

Session II

Moderator: Richard Bucala, MD, PhD, Yale School of Medicine

8:30 AM

The Pathophysiology of Fibrosis
Jack Gauldie, PhD, McMaster University

9:20 AM

The Role of Osteopontin in Fibrosis
Susanne Nicholas, MD, PhD, David Geffen School of Medicine at UCLA

9:40 AM

GBCA and the Induction of Matrix Production
Michael Edward, PhD, University of Glasgow, Glasgow, UK

10:00 AM

Refreshment Break & Poster Viewing

10:30 AM

Impact of GBCA on Fibrocyte Function
Richard Bucala, MD, PhD, Yale School of Medicine

11:00 AM

Fibrosis Roundtable
Moderator: Richard Bucala, MD, PhD, Yale School of Medicine

Panel:
• Richard Bucala, MD, PhD, Yale School of Medicine
• Michael Edward, PhD, University of Glasgow, Glasgow, UK
• Jack Gauldie, PhD, McMaster University
• Susanne Nicholas, MD, PhD, David Geffen School of Medicine at UCLA

Session III: Part 1

Gadolinium: Its Theoretical and Observed Effects in vivo - Models and Their Validity:
Physicochemical Properties of GBCAs and the Link to NSF

Moderator: Ali Abu-Alfa MD, FASN, Yale School of Medicine
Co-Moderator: Phillip H. Kuo MD, PhD, University of Arizona School of Medicine

11:30 AM

Sheffield Experience
John Haylor, PhD, University of Colorado School of Medicine
Sameh K. Morcos, MD, University of Sheffield

11:45 AM

University of California San Francisco Experience
Thomas Hope, MD, University of California, San Francisco

12:00 PM

Lunch

Session III: Part 2
NOTE: CME credit is not available during this session

Gadolinium: Its Theoretical and Observed Effects in vivo - Models and Their Validity:
Physicochemical Properties of GBCAs and the Link to NSF

Moderator: Ali Abu-Alfa MD, FASN, Yale School of Medicine
Co-Moderator: Phillip H. Kuo MD, PhD, University of Arizona School of Medicine

1:00 PM

GBCA Structures and Physiochemical Properties (Guerbet)
Jean-Marc Idée, MS, PharmD, Guerbet

1:15 PM

The Bayer Schering Pharma AG Experience
Hubertus Pietsch, DVM, Bayer-Schering Pharamceuticals
Martin Sieber, PhD, Bayer-Schering Pharmaceuticals

1:30 PM

The GE Healthcare Experience
Benjamin Newton, PhD, GE Healthcare

1:45 PM

The Array Biopharma Experience
April Cox, MS, Array Biopharma

2:00 PM

Panel Discussion

2:30 PM

Refreshment Break & Poster Defense

SESSION IV

Moderator: Jeffrey Weinreb, MD, Yale School of Medicine

3:15 PM

Approach to the Use of GBCA in Patients with Kidney Disease
Ali Abu-Alfa, MD, FASN, Yale School of Medicine

3:45 PM

Panel Discussion - Controversies in the Continued Use of GBCAs
Moderator: Jeffrey Weinreb, MD, Yale School of Medicine

Panel:
• Ali Abu-Alfa, MD, FASN, Yale School of Medicine
• Sameh K. Morcos, FRCS, FFRRCSI, RRCR, University of Sheffield
• Martin Prince, MD, PhD, New York Hospital
• Sundararaman Swaminathan, MD, University of Arkansas for Medical Sciences
• Henrik Thomsen, MD, Copenhagen University Hospital

5:15 PM

Closing Statements
Ali Abu-Alfa, MD, FASN, Yale School of Medicine
Shawn Cowper, MD, Yale School of Medicine, The International Center for Nephrogenic Systemic Fibrosis Research

5:30 PM

Adjourn

Speakers

Symposium Co-Chairs

Ali K. Abu-Alfa, MD

Yale School of Medicine

Shawn Cowper, MD

Yale School of Medicine
The International Center for Nephrogenic Systemic Fibrosis Research

Speakers

Richard Bucala MD, PhD

Yale School of Medicine

April Cox, MS

Array Biopharma

Michael Edward, PhD

University of Glasgow, Glasgow, UK

Jack Gauldie, PhD

McMaster University

Michael Girardi, MD

Yale School of Medicine

John Haylor, PhD

University of Sheffield

Whitney A. High, MD, MEng

University of Colorado, Denver

Thomas Hope, MD

Univeristy of California, San Francisco

Jean-Marc Idée, PharmD, MS

Guerbet

Emanuel Kanal, MD, FACR, FISMRM, AANG

University of Pittsburgh Medical Center

Jonathan Kay, MD

University of Massachusetts Medical School

Ira Krefting, MD

Food and Drug Administration

Phillip H. Kuo MD, PhD

University of Arizona School of Medicine

Philip E. LeBoit, MD

University of California San Francisco

Sameh K. Morcos FRCS, FFRRCSI, FRCR

Sheffield Teaching Hospitals

Benjamin Newton, PhD

GE Healthcare

Susanne Nicholas, MD, PhD

University of California, Los Angeles

Hubertus Pietsch, DVM

Bayer Schering Pharma AG

Martin R. Prince, MD PhD

Cornell & Columbia Universities

Martin A. Sieber, PhD

Bayer Schering Pharma AG

Sundararaman Swaminathan, MD

University of Arkansas for Medical Sciences

Henrik S. Thomsen, MD

University of Copenhagen and Copenhagen University Hospital

Jeffrey C. Weinreb, MD

Yale School of Medicine


Supporters

For opportunities to support or exhibit at this event, please contact Deborah Dunn at deborah.dunn@yale.edu or 203.785.4578.

Presented by

Bronze


Academy Friends

  • • This event is funded in part by the Life Technologies™ Foundation.


Grant Support

The project described is supported by Award Number R13DK088440 from the National Institute Of Diabetes And Digestive And Kidney Diseases. The content of this program is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of Diabetes And Digestive And Kidney Diseases or the National Institutes of Health.

Promotional Partner

Travel & Lodging

Our Location

The New York Academy of Sciences

7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157
212.298.8600

Click here for directions.

Hotels Near 7 World Trade Center

Recommended partner hotel:


Club Quarters, World Trade Center

140 Washington Street
New York, NY 10006
Phone: (212) 577-1133

Located on the south side of the World Trade Center, opposite Memorial Plaza, Club Quarters, 140 Washington Street, is just a short walk to our location. The New York Academy of Sciences is a part of the Club Quarters network. Please feel free to make accommodations on-line to save significantly on hotel costs.

Password: NYAS

Other hotels located near 7 WTC:

Embassy Suites Hotel

      212.945.0100

Millenium Hilton

212.693.2001

Marriott Financial Center

212.385.4900

Millenium Hilton

212.693.2001

Club Quarters, Wall Street

212.269.6400

Eurostars Wall Street Hotel

212.742.0003

Wall Street District Hotel

212.232.7700

Wall Street Inn

212.747.1500

Ritz-Carlton New York, Battery Park

212.344.0800